Jamkas制药公司推出负担得起、可扩展的制造模型,帮助较小的制药公司更快地推出产品。 Jamkas Pharmaceuticals launches affordable, scalable manufacturing model to help smaller drug companies launch products faster.

Jamkas制药公司推出了一个新的第三方制造模式,旨在降低新兴制药品牌的成本,从而加快生产和进入市场。 Jamkas Pharmaceuticals has introduced a new third-party manufacturing model aimed at reducing costs for emerging pharmaceutical brands, enabling faster production and market entry. 该倡议的重点是提供可扩展的、负担得起的制造解决方案,同时不损害质量或监管合规性。 The initiative focuses on providing scalable, affordable manufacturing solutions without compromising quality or regulatory compliance. 该公司表示该模式支持创新, 降低小公司壁垒, 试图将新药品投放市场。 The company says the model supports innovation by lowering barriers for smaller firms seeking to bring new drugs to market.